AU StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

ANTERIS TECHNOLOGIES LTD

7.780

-0.210-2.63%

Volume:16.07K

Turnover:126.49K

Market Cap:756.47M

PE:-2.15

High:8.120

Open:7.990

Low:7.770

Close:7.990

52wk High:13.360

52wk Low:4.260

Shares:97.23M

Float Shares:27.69M

Volume Ratio:0.81

T/O Rate:0.06%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-3.622

EPS(LYR):-5.328

ROE:-2698.53%

ROA:-268.96%

PB:144.63

PE(LYR):-1.46

Loading ...

Overview Company News Filings

Institutions profited after Anteris Technologies Global Corp.'s (ASX:AVR) market cap rose AU$609m last week but individual investors profited the most

Simply Wall St.

Anteris Technologies Announces $90 Million Private Placement to Medtronic Subsidiary

Anteris Technologies Prices $200 Million Public Offering; Shares Surge 20%

MT Newswires Live

BUZZ-Anteris Technologies jumps after announcing stock sale plans, Medtronic investment

Anteris Says Heart Valve Clinical Data Shows No Valve-Related Mortality

MT Newswires Live

Anteris Technologies posts $16.8 million R&D expenses and $5.8 million SG&A expenses in Q3 2025

Anteris Technologies Receives US FDA Approval for Transcatheter Heart Valve Trial; Shares Up 11%

MT Newswires Live

BRIEF-Anteris Technologies Global Corp Says FDA Approves Duravr THV Global Pivotal Trial

Anteris Reports One-Year Outcomes for Transcatheter Heart Valve in Severe Aortic Stenosis Patients with Small Aortic Annuli

MT Newswires Live

Anteris Technologies Signs Subscription Agreements for Nearly AU$39 Million Placement; Shares Down 9%

MT Newswires Live

Anteris Says First Calcific Aortic Stenosis Patients Treated Under Transcatheter Heart Valve Global Pivotal Trial; Shares Down 3%

MT Newswires Live

BRIEF-Anteris Technologies Global Corp Seeks Trading Halt in ASX Securities

Anteris Technologies Receives Danish Regulatory Clearance for Transcatheter Heart Valve Trial; Shares Up 5%

MT Newswires Live

Investors bid Anteris Technologies Global (ASX:AVR) up AU$29m despite increasing losses YoY, taking five-year CAGR to 13%

Simply Wall St.

Anteris Technologies Says Patient Enrollment in Global Pivotal Registration Trial Expected to Begin in Q4

MT Newswires Live

Press Release: Anteris Technologies Global Corp. Announces Postponement of Special Meeting of Stockholders

Anteris Technologies Enters into Agreement with Switchback Medical for Development, Manufacturing Services

MT Newswires Live

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/AVR.AU/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"AVR.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"AVR.AU\",,,,,undefined,":{"symbol":"AVR.AU","market":"AU","secType":"STK","nameCN":"ANTERIS TECHNOLOGIES LTD","latestPrice":7.78,"timestamp":1770700320000,"preClose":7.99,"halted":0,"volume":16072,"delay":0,"changeRate":-0.026282853566958694,"nameEN":"ANTERIS TECHNOLOGIES LTD","floatShares":27691457,"shares":97232054,"eps":-3.621570782223014,"marketStatus":"Closed","change":-0.21,"latestTime":"02-10 16:12:00 AEDT","open":7.99,"high":8.12,"low":7.77,"amount":126490,"amplitude":0.043805,"askPrice":8.45,"askSize":1000,"bidPrice":7.77,"bidSize":298,"shortable":3,"etf":0,"ttmEps":-3.621570782223014,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":0,"beginTime":1770764400000},"marketStatusCode":5,"adr":0,"exchange":"ASX","adjPreClose":7.99,"openAndCloseTimeList":[[1770678000000,1770699600000]],"volumeRatio":0.814003,"lotSize":1,"tradeCurrency":"AUD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"AVR.AU\",,,,,undefined,":{"symbol":"AVR.AU","floatShares":27691457,"roa":"-268.96%","roe":"-2698.53%","lyrEps":-5.327655,"volumeRatio":0.814003,"shares":97232054,"dividePrice":0,"high":8.12,"amplitude":0.043805,"preClose":7.99,"low":7.77,"week52Low":4.26,"pbRate":"144.63","psRate":"250.05","week52High":13.36,"institutionHeld":0,"latestPrice":7.78,"committee":-0.540832,"eps":-3.621570782223014,"divideRate":0,"volume":16072,"delay":0,"ttmEps":-3.621570782223014,"open":7.99,"prevYearClose":7.66,"prevWeekClose":7.4,"prevMonthClose":8.84,"prevQuarterClose":7.66,"fiveDayClose":8.61,"twentyDayClose":6.97,"sixtyDayClose":6.03},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/AVR.AU\",params:#limit:5,,,undefined,":[{"market":"AU","date":"2024-12-11","symbol":"AVR.AU","reason":null,"defaultRemindTime":1733871600000,"announcedDate":"2024-09-05","type":"delisting","dateTimestamp":1733835600000},{"market":"AU","date":"2024-10-15","symbol":"AVR.AU","reason":null,"defaultRemindTime":1728946800000,"announcedDate":"2024-09-05","type":"delisting","dateTimestamp":1728910800000}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"AVR.AU\",market:\"AU\",,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"AVR.AU\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2605286922","title":"Institutions profited after Anteris Technologies Global Corp.'s (ASX:AVR) market cap rose AU$609m last week but individual investors profited the most","url":"https://stock-news.laohu8.com/highlight/detail?id=2605286922","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605286922?lang=en_us&edition=fundamental","pubTime":"2026-01-24 04:56","pubTimestamp":1769201762,"startTime":"0","endTime":"0","summary":"Key Insights The considerable ownership by individual investors in Anteris Technologies Global indicates that they...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6022000-choice1-main-header/1585186795401","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6022000-choice1-main-header/1585186795401"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/healthcare/asx-avr/anteris-technologies-global-shares/news/institutions-profited-after-anteris-technologies-global-corp","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/healthcare/asx-avr/anteris-technologies-global-shares/news/institutions-profited-after-anteris-technologies-global-corp","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK7007","AVR","BK4082","BK7126","AVR.AU"],"gpt_icon":0},{"id":"2605849889","title":"Anteris Technologies Announces $90 Million Private Placement to Medtronic Subsidiary","url":"https://stock-news.laohu8.com/highlight/detail?id=2605849889","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605849889?lang=en_us&edition=fundamental","pubTime":"2026-01-22 19:19","pubTimestamp":1769080777,"startTime":"0","endTime":"0","summary":"Anteris Technologies Global Corp. has announced a private placement with Covidien Group S.à r.l., a wholly owned subsidiary of Medtronic plc. Under the agreement, Anteris will issue and sell 15,652,173 shares of its common stock at a price of $5.75 per share, raising approximately $90 million in gross proceeds before fees and expenses. The company plans to use the net proceeds, along with funds from a concurrent underwritten offering, to support its growth and advance its clinical strategy. As part of the transaction, Anteris will enter into a registration rights agreement, granting the investor the right to require registration and sale of the shares.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Anteris Technologies Global Corp. pub","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260122:nNDL5HngVw:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0070302665.USD","IE00BVYPNV92.GBP","LU2112291526.USD","LU0122379950.USD","BK4533","BK7126","LU1023059063.AUD","LU1571399168.USD","LU0158827948.USD","IE00BQXX3F31.USD","LU0162691827.USD","LU0976567544.SGD","LU0211326755.USD","LU1244550494.USD","LU1989764664.SGD","LU2089284900.SGD","IE00B3PB1722.GBP","MDT","BK4566","LU2468319806.SGD","LU1057294990.SGD","LU1244550577.SGD","LU2089984988.USD","LU2111349929.HKD","LU0265550359.USD","BK7007","LU1983299246.USD","BK4585","AVR","IE00B3T34201.USD","BK4082","LU1061106388.HKD","IE00BQXX3D17.EUR","AVR.AU","LU1244550221.USD","IE000M9KFDE8.USD","BK4588","IE00BGHQF631.EUR","LU0320765489.SGD","LU0211331839.USD","LU1116320901.HKD","LU2023251221.USD","IE00BQXX3C00.GBP","LU2028103732.USD","LU0208291251.USD","LU2089283258.USD","LU1506573853.SGD","LU0314106906.USD","LU0265550946.USD","LU0158827781.USD"],"gpt_icon":0},{"id":"2605270841","title":"Anteris Technologies Prices $200 Million Public Offering; Shares Surge 20%","url":"https://stock-news.laohu8.com/highlight/detail?id=2605270841","media":"MT Newswires Live","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605270841?lang=en_us&edition=fundamental","pubTime":"2026-01-21 13:02","pubTimestamp":1768971760,"startTime":"0","endTime":"0","summary":"Anteris Technologies (ASX:AVR) priced its $200 million public offering of around 34.8 million shares at $5.75 apiece, according to a Wednesday Australian bourse filing.The offering is expected to clos","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["AVR.AU","BK7126","BK7007"],"gpt_icon":0},{"id":"2605321142","title":"BUZZ-Anteris Technologies jumps after announcing stock sale plans, Medtronic investment","url":"https://stock-news.laohu8.com/highlight/detail?id=2605321142","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605321142?lang=en_us&edition=fundamental","pubTime":"2026-01-21 06:21","pubTimestamp":1768947717,"startTime":"0","endTime":"0","summary":"BUZZ-Anteris Technologies jumps after announcing stock sale plans, Medtronic investment** U.S.-listed shares of heart-valve maker Anteris Technologies AVR.O jump ~40% to $8.04 after hours after it unveils proposed stock offering, Medtronic MDT.N investment** Co, whose principal executive offices are in Australia, announces $200 mln stock offering** In addition, it agreed to sell to MDT up to $90 mln of stock in private placement, subject to minimum purchase of 16% and maximum purchase of 19.99% of its outstanding shares after the offering** Anteris says plans to use net offering proceeds from both financings for ongoing recruitment and study execution of the DurAVR Transcatheter Heart Valve global trial for patients with severe aortic stenosis  and expansion of manufacturing capabilities, among other uses** Barclays, Wells Fargo and Cantor Fitzgerald joint bookrunners** Co has ~41.2 mln shares outstanding for roughly $240 mln market cap** AVR shares closed up 12.5% at $5.75 on Tues, up","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260120:nL6N3YL1BY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1244550221.USD","LU2028103732.USD","LU1983299246.USD","LU1116320901.HKD","LU1506573853.SGD","LU0320765489.SGD","LU0964806797.USD","LU0047473722.EUR","BK7007","IE00BVYPNV92.GBP","LU0345777147.USD","LU0265550359.USD","LU0345777659.USD","LU1291159041.SGD","LU1023059063.AUD","LU0158827948.USD","IE000M9KFDE8.USD","LU0072461881.USD","LU0314106906.USD","AVR","LU0997586606.USD","LU0070302665.USD","LU0122379950.USD","IE00BDGV0183.EUR","IE00B3PB1722.GBP","BK4588","LU1035777561.USD","LU1989764664.SGD","LU0345770308.USD","LU1791807156.HKD","LU1989771016.USD","LU0550127509.SGD","LU2023251221.USD","LU1668664300.SGD","LU2089284900.SGD","LU0048578792.EUR","IE00B42XCP33.USD","LU0211326755.USD","LU1064927863.SGD","BARC.UK","BK5152","BK4082","LU0496365809.HKD","LU0432979614.USD","LU2112291526.USD","AVR.AU","MDT","BK4566","IE00BFXG1179.USD","IE00BGHQF631.EUR"],"gpt_icon":0},{"id":"2584616078","title":"Anteris Says Heart Valve Clinical Data Shows No Valve-Related Mortality","url":"https://stock-news.laohu8.com/highlight/detail?id=2584616078","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584616078?lang=en_us&edition=fundamental","pubTime":"2025-11-17 13:00","pubTimestamp":1763355638,"startTime":"0","endTime":"0","summary":"Anteris Technologies  said clinical outcomes for its transcatheter heart valve DurAVR in 100 severe aortic stenosis patients with small aortic annuli showed no moderate or severe paravalvular leaks and no valve-related mortality, according to a Monday filing with the Australian bourse.The results also showed 97% freedom from moderate or severe prosthesis-patient mismatch  in a group of small annuli patients, the filing said.Moderate to severe PPM is independently associated with reduced survival and increased risk of structural valve deterioration, the filing added.Shares of the company fell 2% in recent Monday trade.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7126","BK7123","PPM.AU","BK7007","BK7160","AVR.AU"],"gpt_icon":0},{"id":"2583581693","title":"Anteris Technologies posts $16.8 million R&D expenses and $5.8 million SG&A expenses in Q3 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2583581693","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583581693?lang=en_us&edition=fundamental","pubTime":"2025-11-13 06:53","pubTimestamp":1762987981,"startTime":"0","endTime":"0","summary":"Anteris Technologies Global Corp. reported net operating cash outflows of $59.3 million for the nine months ended September 30, 2025, reflecting increased clinical, regulatory, and manufacturing activities related to the PARADIGM Trial. For the three months ended September 30, 2025, research and development expenses were $16.8 million, and selling, general and administrative expenses were $5.8 million. The company held $9.1 million in cash and cash equivalents as of September 30, 2025. During the quarter, Anteris advanced its quality management system, expanded manufacturing capacity, and received regulatory approvals to commence the PARADIGM Trial in the U.S. and Denmark.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Anteris Technolo","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251112:nNDL7vwwSt:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","BK7126","AVR.AU","LU2210149790.SGD","BK4585","LU2210150020.SGD","AVR","IE00BKPKM429.USD","IE00B3QW5Z07.USD","IE00B64PRP62.GBP","LU0314104364.USD","BK4082","BK4112","NDAQ","LU2095319765.USD","IE00BGHQF748.EUR","BK7007"],"gpt_icon":0},{"id":"2580254834","title":"Anteris Technologies Receives US FDA Approval for Transcatheter Heart Valve Trial; Shares Up 11%","url":"https://stock-news.laohu8.com/highlight/detail?id=2580254834","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2580254834?lang=en_us&edition=fundamental","pubTime":"2025-11-03 11:25","pubTimestamp":1762140321,"startTime":"0","endTime":"0","summary":"Anteris Technologies  received US Food and Drug Administration approval to start its Paradigm clinical trial evaluating the DurAVR transcatheter heart valve  in patients with severe calcific aortic stenosis, according to a Monday filing with the Australian bourse.Calcific aortic stenosis is a progressive heart condition where calcium deposits on the aortic valve, causing it to thicken and narrow, obstructing blood flow.The trial will evaluate the company's DurAVR THV against commercially available transcatheter aortic valve replacements and supports a future pre-market approval application to the US FDA, per the filing.Shares rose 11% in afternoon trade Monday.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7007","AVR.AU","BK7126"],"gpt_icon":0},{"id":"2580231189","title":"BRIEF-Anteris Technologies Global Corp Says FDA Approves Duravr THV Global Pivotal Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2580231189","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2580231189?lang=en_us&edition=fundamental","pubTime":"2025-11-03 06:11","pubTimestamp":1762121463,"startTime":"0","endTime":"0","summary":"BRIEF-Anteris Technologies Global Corp Says FDA Approves Duravr THV Global Pivotal TrialNov 3 (Reuters) - Anteris Technologies Global Corp AVR.O:FDA APPROVES DURAVR THV GLOBAL PIVOTAL TRIALFurther company coverage: AVR.O ((Reuters.Briefs@thomsonreuters.com;))","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251102:nFWN3WE00J:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AVR","BK7126","AVR.AU","BK4082","BK7007"],"gpt_icon":0},{"id":"2579947210","title":"Anteris Reports One-Year Outcomes for Transcatheter Heart Valve in Severe Aortic Stenosis Patients with Small Aortic Annuli","url":"https://stock-news.laohu8.com/highlight/detail?id=2579947210","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2579947210?lang=en_us&edition=fundamental","pubTime":"2025-10-29 13:37","pubTimestamp":1761716230,"startTime":"0","endTime":"0","summary":"Anteris Technologies  said clinical outcomes for the DurAVR transcatheter heart valve in symptomatic severe aortic stenosis patients with small aortic annuli showed single-digit mean gradients and large effective orifice areas, no moderate or severe paravalvular leaks, as well as no valve-related mortality at one year, according to a Wednesday Australian bourse filing.The pooled group included 65 patients with small aortic annuli implanted with the DurAVR valve from the ongoing EMBARK study and the US early feasibility study. It reported an effective orifice area of 2.1 square centimeters, with a variation of 0.2 square centimeters, and a mean pressure gradient of 8.6 millimeters of mercury, with a variation of 2.6 millimeters of mercury.It also showed low prosthesis-patient mismatch at 30 days, at just 1.5%.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7007","AVR.AU","BK7126"],"gpt_icon":0},{"id":"2578602050","title":"Anteris Technologies Signs Subscription Agreements for Nearly AU$39 Million Placement; Shares Down 9%","url":"https://stock-news.laohu8.com/highlight/detail?id=2578602050","media":"MT Newswires Live","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2578602050?lang=en_us&edition=fundamental","pubTime":"2025-10-28 11:15","pubTimestamp":1761621310,"startTime":"0","endTime":"0","summary":"Anteris Technologies  signed binding subscription agreements for a AU$38.5 million placement through the issue of 5.1 million shares and CHESS depositary interests , according to a Tuesday filing with the Australian bourse.The placement involves an offer of 2.3 million new common shares at $4.90 apiece, to raise about $11.5 million, with each share including an attaching warrant to acquire a share at $7.50 apiece, expiring five years from the date of issue, the filing said.The offer also includes 2.8 million new CDIs at a AU$7.50 apiece, to raise about AU$20.9 million, with each CDI including an attaching warrant to acquire a CDI at AU$11.50 apiece, expiring five years from the date of issue.The proceeds will support growth and clinical strategy execution, including recruitment for the DurAVR transcatheter heart valve global pivotal trial, study execution, and manufacturing expansion, per the filing.Shares fell 9% in afternoon trade Tuesday.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7007","BK7126","AVR.AU"],"gpt_icon":0},{"id":"2578025876","title":"Anteris Says First Calcific Aortic Stenosis Patients Treated Under Transcatheter Heart Valve Global Pivotal Trial; Shares Down 3%","url":"https://stock-news.laohu8.com/highlight/detail?id=2578025876","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2578025876?lang=en_us&edition=fundamental","pubTime":"2025-10-28 10:58","pubTimestamp":1761620328,"startTime":"0","endTime":"0","summary":"Anteris Technologies  said the first patients in the DurAVR transcatheter heart valve global pivotal trial for patients with severe calcific aortic stenosis were enrolled and treated in Denmark, according to a Tuesday Australian bourse filing.The trial seeks to evaluate the safety and effectiveness of the DurAVR transcatheter heart valve compared to commercially available transcatheter aortic valve replacements, the filing said. The company plans to enroll around 1,000 patients in the \"All-Comers Randomized Cohort,\" and it will assess non-inferiority on a primary composite endpoint of all-cause mortality, all stroke, and cardiovascular hospitalization one year after the procedure.The trial builds on the firm's existing clinical data set of 130 patients successfully treated with the transcatheter heart valve, including de novo aortic stenosis cases, valve-in-valve patients, as well as those with complex anatomies such as bicuspid aortic valve patients.The company plans to expand the tri","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7007","AVR.AU","BK7126"],"gpt_icon":0},{"id":"2577302365","title":"BRIEF-Anteris Technologies Global Corp Seeks Trading Halt in ASX Securities","url":"https://stock-news.laohu8.com/highlight/detail?id=2577302365","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2577302365?lang=en_us&edition=fundamental","pubTime":"2025-10-24 06:51","pubTimestamp":1761259874,"startTime":"0","endTime":"0","summary":"BRIEF-Anteris Technologies Global Corp Seeks Trading Halt in ASX SecuritiesOct 24 (Reuters) - Anteris Technologies Global Corp AVR.O:SEEKS TRADING HALT PENDING ANNOUNCEMENT ON PROPOSED CAPITAL RAISINGFurther company coverage: AVR.O ((Reuters.Briefs@thomsonreuters.com;))","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251023:nTUE6HLCCS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7126","BK7007","AVR","BK4082","AVR.AU"],"gpt_icon":0},{"id":"2575672197","title":"Anteris Technologies Receives Danish Regulatory Clearance for Transcatheter Heart Valve Trial; Shares Up 5%","url":"https://stock-news.laohu8.com/highlight/detail?id=2575672197","media":"MT Newswires Live","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575672197?lang=en_us&edition=fundamental","pubTime":"2025-10-16 10:57","pubTimestamp":1760583420,"startTime":"0","endTime":"0","summary":"Anteris Technologies  secured regulatory clearance from the Danish Medicines Agency to initiate the DurAVR transcatheter heart valve global pivotal trial in patients with severe calcific aortic stenosis, according to a Thursday filing with the Australian bourse.Calcific aortic stenosis is a progressive heart condition where calcium deposits on the aortic valve, causing it to thicken and narrow, obstructing blood flow.The recruitment of patients at Danish centers is anticipated to begin in the fourth quarter of the year, the filing said.Additionally, an investigational device exemption application is under review by the US Food and Drug Administration, per the filing.Shares rose 5% in afternoon trade on Thursday.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7007","AVR.AU","BK7126"],"gpt_icon":0},{"id":"2574459483","title":"Investors bid Anteris Technologies Global (ASX:AVR) up AU$29m despite increasing losses YoY, taking five-year CAGR to 13%","url":"https://stock-news.laohu8.com/highlight/detail?id=2574459483","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2574459483?lang=en_us&edition=fundamental","pubTime":"2025-10-11 04:40","pubTimestamp":1760128843,"startTime":"0","endTime":"0","summary":"When we invest, we're generally looking for stocks that outperform the market average. And the truth is, you can make...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6022000-choice1-main-header/1585186795401","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6022000-choice1-main-header/1585186795401"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/healthcare/asx-avr/anteris-technologies-global-shares/news/investors-bid-anteris-technologies-global-asxavr-up-au29m-de","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/healthcare/asx-avr/anteris-technologies-global-shares/news/investors-bid-anteris-technologies-global-asxavr-up-au29m-de","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["AVR.AU","AVR","BK4082","BK7126","ISBC","BK7007","BK4211"],"gpt_icon":0},{"id":"2571364647","title":"Anteris Technologies Says Patient Enrollment in Global Pivotal Registration Trial Expected to Begin in Q4","url":"https://stock-news.laohu8.com/highlight/detail?id=2571364647","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2571364647?lang=en_us&edition=fundamental","pubTime":"2025-09-30 07:59","pubTimestamp":1759190388,"startTime":"0","endTime":"0","summary":"Anteris Technologies  said the patient enrollment in the its global pivotal registration trial is expected to begin in the fourth quarter, according to a Tuesday Australian bourse filing.Enrollment was initially expected to begin in the third quarter.It submitted a formal response to the US Federal Drug Administration's  request for additional information regarding the investigational device exemption. The submission includes the clinical study protocol and demonstrates the DurAVR transcatheter heart valve system was developed and tested for use \"appropriately\" in the global pivotal trial, per the filing.A special meeting of the firm's stockholders, held on Monday, approved the grant of a waiver by ASX from certain listing rules, allowing Anteris to issue new securities without obtaining the approval of its stockholders.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7126","AVR.AU","BK7007"],"gpt_icon":0},{"id":"2564328416","title":"Press Release: Anteris Technologies Global Corp. Announces Postponement of Special Meeting of Stockholders","url":"https://stock-news.laohu8.com/highlight/detail?id=2564328416","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2564328416?lang=en_us&edition=fundamental","pubTime":"2025-09-04 13:42","pubTimestamp":1756964520,"startTime":"0","endTime":"0","summary":"The Special Meeting has been postponed to provide the Company's stockholders with additional time to vote in order to facilitate broader participation. The Company's Board of Directors unanimously recommends that you vote FOR the proposals identified in the Company's definitive Proxy Statement for the Special Meeting , which was filed with the Securities and Exchange Commission  on August 18, 2025.If you have already voted your shares of Common Stock or directed CHESS Depositary Nominees Pty Ltd  to vote your CHESS Depositary Interests  by completing the CDI Voting Instruction Form and you do not desire to change your vote, your prior vote will remain voted without the need for you to take any additional action.The Company filed the definitive Proxy Statement with the SEC on August 18, 2025, which should be read in conjunction with this notice. To the","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4232","AVR","BK4022","BK4082","AVR.AU","BK7007","R","BK7126"],"gpt_icon":0},{"id":"2555901160","title":"Anteris Technologies Enters into Agreement with Switchback Medical for Development, Manufacturing Services","url":"https://stock-news.laohu8.com/highlight/detail?id=2555901160","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2555901160?lang=en_us&edition=fundamental","pubTime":"2025-07-30 14:37","pubTimestamp":1753857478,"startTime":"0","endTime":"0","summary":"Anteris Technologies  said on Monday it entered into an amended and restated master services agreement with Switchback Medical, under which Switchback will provide development and manufacturing services, including engineering and testing services, according to a Wednesday Australian bourse filing.The agreement expires on March 31, 2028, and will automatically renew for successive one-year terms unless terminated by one of the firms.Anteris granted Switchback a limited, exclusive, revocable, non-sublicensable, fully paid-up, royalty-free license to certain of its intellectual property to be used only for manufacturing during the term of the agreement.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7007","BK7126","AVR.AU"],"gpt_icon":0}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":17,"code":"91000000","status":"200"}]}}